O080 A double-blind, placebo-controlled, randomised trial of extracorporeal shockwave therapy as a novel treatment for intermittent claudication.

Abstract Introduction Intermittent claudication (IC) is a prevalent manifestation of peripheral arterial disease and affects about 3% the UK population. Current guidance for management nonlife limiting IC supervised exercise best medical therapy. Supervised however not readily available across nation has poor recruitment retention rates. Pilot data demonstrated that Extracorporeal ShockWave Therapy (ESWT) effective improving walking distance in patients with IC. This study aims to consider its effectiveness quality life (QoL). Methods In double-blind, sham-controlled, randomised trial, were 1:1 ratio ESWT or sham treatment. The primary endpoint was change physical functioning at 12-week follow-up, as measured by SF-36. Secondary endpoints included changes distances ABPI. Results 138 randomised. group had significantly higher score 12 weeks (Mdn 41 vs 34, z=-2.1, p=0.033). They also longer 125 88, z=-2.9, p=0.004) maximum 179 129, z=-2.4, p=0.013) distances. from baseline 12-weeks greater 51 24, z=-2.8, p<0.01) 63 17, z=-4 distance. No difference observed Conclusion demonstrates safe, well tolerated clinically QoL Take-home message shockwave therapy improves distances, could potentially be used non-invasive adjunct institutions available.